Literature DB >> 17325977

Environmental, inhaled and ingested causes of pulmonary fibrosis.

Nasreen Khalil1, Andrew Churg, Nestor Muller, Robert O'Connor.   

Abstract

Pulmonary fibrosis is a general term that refers to a collection of connective tissue around alveolar structures. There are over 200 disorders where the lungs may be involved in a fibrotic response. To determine the cause of pulmonary fibrosis requires an in depth understanding of the pathogenesis of pulmonary fibrosis and breadth of knowledge of the causative agents and associated disorders that may lead to pulmonary fibrosis. A comprehensive evaluation of the patient is absolutely essential, starting with detailed history that includes an occupational and environmental history because fibrogenic exposures can occur in many settings. Equally important is a history of ingestion of pharmaceutical or nonpharmaceutical substances. A physical examination and judicious investigations are always a part of any comprehensive clinical assessment but they are not commonly helpful in elucidating the cause of most pulmonary fibrotic disorders. Although, a chest film is invariably done, a logical and strongly recommended next step is a high-resolution computed tomography (HRCT). HRCT provides a better assessment of the radiological pattern, may suggest a diagnosis as well as direct the site, and type of lung biopsy. If the history and investigations do not lead to a diagnosis then a lung biopsy is required. Prevention or removal of the inciting agent is critical to the treatment of these disorders and in some instances corticosteroids may be of help.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17325977     DOI: 10.1080/01926230601064787

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  6 in total

Review 1.  Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Authors:  Andrea T Borchers; Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

2.  Pulmonary inflammation triggered by ricin toxin requires macrophages and IL-1 signaling.

Authors:  Meghan L Lindauer; John Wong; Yoichiro Iwakura; Bruce E Magun
Journal:  J Immunol       Date:  2009-06-26       Impact factor: 5.422

Review 3.  Stem Cell-Based Therapy in Idiopathic Pulmonary Fibrosis.

Authors:  Marek Barczyk; Matthias Schmidt; Sabrina Mattoli
Journal:  Stem Cell Rev Rep       Date:  2015-08       Impact factor: 5.739

Review 4.  Monitoring and management of fibrosing interstitial lung diseases: a narrative review for practicing clinicians.

Authors:  Anoop M Nambiar; Christopher M Walker; Jeffrey A Sparks
Journal:  Ther Adv Respir Dis       Date:  2021 Jan-Dec       Impact factor: 5.158

5.  The natural history of progressive fibrosing interstitial lung diseases.

Authors:  Kevin K Brown; Fernando J Martinez; Simon L F Walsh; Victor J Thannickal; Antje Prasse; Rozsa Schlenker-Herceg; Rainer-Georg Goeldner; Emmanuelle Clerisme-Beaty; Kay Tetzlaff; Vincent Cottin; Athol U Wells
Journal:  Eur Respir J       Date:  2020-06-25       Impact factor: 16.671

6.  Management of patients with fibrosing interstitial lung diseases.

Authors:  Lee E Morrow; Daniel Hilleman; Mark A Malesker
Journal:  Am J Health Syst Pharm       Date:  2022-01-24       Impact factor: 2.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.